癌症中的佐:临床前证据和结构-活性关系的系统审查
Gabriel Mardale1,2, Alexandra Prodea1,2, Andreea Munteanu1,2
1Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timișoara, Romania.
Pharmaceuticals (Basel, Switzerland)
|January 28, 2026
概括
在临床前研究中,佐衍生物显示出作为抗癌剂的前景,表现出细胞毒性和减少瘤质量. 需要使用严格的方法进行进一步的研究,以确认它们的治疗潜力和安全性.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 三醇是药物化学中的多功能异环.
- 佐特醇衍生物被探索为强大的抗癌药物候选者.
- 缺乏对临床前佐醇抗癌研究的综合性审查.
研究的目的:
- 审查前临床证据关于黄衍生物作为抗癌药物.
- 专注于细胞毒性,作用机制,结构-活性关系和方法论的严谨性.
- 为癌症治疗确定有前途的佐特醇衍生物.
主要方法:
- 在PubMed,Scopus和Web of Science的系统文献搜索.
- 包括41项基于选择标准的研究.
- 使用QUIN (体外) 和SYRCLE (体内) 工具进行偏差风险评估.
主要成果:
- 三醇衍生物分为N-,C-,化和有机金属化合物.
- 试验室研究显示,通过细胞亡和细胞循环停止,细胞毒性较强.
- 在体内研究表明,剂量依赖的瘤质量减少,肝毒性最小.
结论:
- 佐特醇衍生物是有希望的抗癌候选物.
- 机理学和毒性数据有限,偏差风险中等,需要谨慎.
- 未来的研究需要严格的方法来充分评估治疗潜力和安全性.
相关概念视频
Structure-Activity Relationships and Drug Design
1.8K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K
Local Anesthetics: Chemistry and Structure-Activity Relationship
6.6K
Local anesthetics (LAs) are drugs that induce a temporary loss of sensation in a limited body area, preventing pain. Cocaine was the first local anesthetic discovered in the late 19th century. Cocaine is a benzoic acid ester obtained from the leaves of coca shrubs and was often used for its psychotropic effects. Cocaine was first isolated in 1860 by Albert Niemann. Sigmund Freud studied the physiological actions of cocaine. Carl Koller later introduced it into clinical practice in 1884 as a...
6.6K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.8K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.8K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
The Evidence for Evolution
48.0K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
48.0K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
971
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
971


